ABIVAX Société Anonyme (EPA:ABVX)
France
· Delayed Price · Currency is EUR | Market Cap | 7.75B |
| Revenue (ttm) | 5.31M |
| Net Income (ttm) | -293.52M |
| Shares Out | 77.83M |
| EPS (ttm) | -4.46 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 125,243 |
| Average Volume | 101,403 |
| Open | 100.60 |
| Previous Close | 102.60 |
| Day's Range | 96.00 - 103.60 |
| 52-Week Range | 4.51 - 132.00 |
| Beta | -0.42 |
| RSI | 42.48 |
| Earnings Date | Mar 23, 2026 |
About ABIVAX Société Anonyme
ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Its lead drug candidate includes obefazimod that is in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis, as well as in Phase 2b clinical trial to treat patients with Crohn’s disease. The company was incorporated in 2013 and is headquartered in Paris, France. [Read more]
Financial Performance
In 2024, ABIVAX Société Anonyme's revenue was 10.79 million, an increase of 135.94% compared to the previous year's 4.57 million. Losses were -176.24 million, 19.3% more than in 2023.
Financial StatementsNews
2 Reasons Abivax Stock Could 10X by 2036
Abivax's leading candidate could be a breakthrough treatment in ulcerative colitis. The medicine will likely target several other immunology conditions as well.
BTIG Reiterates Buy Rating for Abivax (ABVX) with $150 Price Target | ABVX Stock News
BTIG Reiterates Buy Rating for Abivax (ABVX) with $150 Price Target | ABVX Stock News
Wedbush Rates Abivax (ABVX) as Underperform with Cautious Outlook
Wedbush Rates Abivax (ABVX) as Underperform with Cautious Outlook
Abivax (ABVX) Highlights Promising Obefazimod Data at ECCO Congress
Abivax (ABVX) Highlights Promising Obefazimod Data at ECCO Congress
Abivax Presents First Evidence of Anti-Fibrotic Activity for Obefazimod Alongside New Clinical Efficacy and Safety Analyses in Inflammatory Bowel Disease at ECCO 2026
Abivax Presents First Evidence of Anti-Fibrotic Activity for Obefazimod Alongside New Clinical Efficacy and Safety Analyses in Inflammatory Bowel Disease at ECCO 2026
Alger Mid Cap Growth Fund Q4 2025 Portfolio Update
Class A shares of the Alger Mid Cap Growth Fund outperformed the Russell Midcap Growth Index during the fourth quarter of 2025. Cidara Therapeutics, Inc., Natera, Inc., and Abivax were among the top c...
Missed Out on Eli Lilly? 2 Healthcare Stocks With Big Catalysts on the Horizon.
Eli Lilly set the bar high, and it will be hard for other drugmakers to match its performance. Viking Therapeutics and Abivax are developing promising candidates.
Better Long-Term Buy: This Emerging Player or the Industry Leader?
AbbVie is a well-established drugmaker with fast-growing immunology products and a solid dividend program. Abivax could challenge pharmaceutical giants like AbbVie in a niche of the immunology market.
Harbor Small Cap Growth Fund Q4 2025 Portfolio Performance
From a sector perspective, strength within Industrials and Information Technology offset relative weakness in Health Care. The October earnings report reinforced confidence in Comfort Systems' ability...
Abivax CEO dismisses 'noise' around rumored Eli Lilly bid
Abivax Chief Executive Marc de Garidel dismissed as "noise" reports in the French press that pharmaceutical giant Eli Lilly may take over his company, and said market speculation about an ongoing revi...
Prediction: This Healthcare Stock Could Soar by 72% in 2026
Abivax has a potential transformative medicine in its pipeline that is attracting attention from other drugmakers. If the biotech gets acquired this year, its shares could soar.
Abivax: Don't Just Buy The Rumor, Buy The Fundamentals
Abivax (ABVX) remains a Buy, driven by obefazimod's strong UC data and significant multi-billion dollar market potential. ABVX is a credible M&A target, with Eli Lilly and other pharma giants rumored ...
France has had no request for investment approval in biotech Abivax - official
France's finance ministry has received no request seeking investment approval in Abivax and has had no contact with Eli Lilly , a ministry official said on Monday, following media reports that the U.S...
Abivax stock rockets 30% on Eli Lilly takeover speculation
Abivax stock (EPA: ABVX) surged roughly 30% in early Paris trading Monday after French media reported that US pharmaceutical giant Eli Lilly was preparing a €15 billion ($17.5 billion) acquisition off...
Abivax Surges on Report Eli Lilly is Preparing $17.5 Billion Bid
Stock in the French company has been rising steadily since late July, and climbed as much as 30% in early trading Monday.
Abivax shares soar 23% as media report reignites M&A chatter
Shares in Abivax soared 23%, exceeding 121 euros, on Monday after a media report said U.S. pharma giant Eli Lilly was still interested in buying the French biotech company.
A little-known biotech stock has become a prime takeover target after surging nearly 1,700% last year
Abivax stock rallied in 2025, far outpacing peers, as the French biotech surprised investors with a stellar data readout in July for its lead asset – an ulcerative colitis medicine. Now, analysts say ...
Abivax Provides 2026 Corporate Outlook
Abivax Provides 2026 Corporate Outlook New market insights indicate significant future expansion of the ulcerative colitis (UC) market, with obefazimod well positioned to become a future market leader...
Abivax: Here's Why Eli Lilly Could Want Its Oral Ulcerative Colitis Therapy
Abivax surged 1,470% YTD, driven by Obefazimod's clinical progress and takeover speculation, but I rate it Hold due to valuation risk. Obefazimod, a first-in-class oral therapy for ulcerative colitis,...
Why Abivax Stock Was on Fire Today
New speculation arose about a potential buyout from a very deep-pocketed strategic investor. These first started to swirl in mid-December.
Abivax to be Added to Nasdaq Biotechnology Index
Abivax to be Added to Nasdaq Biotechnology Index PARIS, France – December 18, 2025 – 10:05 pm CET – Abivax SA (Euronext Paris: FR0012333284 – ABVX / Nasdaq: ABVX) (“Abivax” or the “Company”), a clinic...
Abivax Announces Acceptance of 22 Abstracts Evaluating Obefazimod in Inflammatory Bowel Disease at ECCO 2026, Featuring an Oral Presentation on Preclinical Anti-Fibrotic Findings
Abivax Announces Acceptance of 22 Abstracts Evaluating Obefazimod in Inflammatory Bowel Disease at ECCO 2026, Featuring an Oral Presentation on Preclinical Anti-Fibrotic Findings
Abivax: "Strong Buy" On Obefazimod New UC Data And Maintenance Results Coming Q2 2026
Abivax SA (ABVX) retains a "Strong Buy" rating, driven by positive phase 3 ABTECT induction data for obefazimod in moderate-to-severe ulcerative colitis. Upcoming catalysts include 44-week maintenance...
What's Happening With French Biotech Abivax Stock On Wednesday?
Abivax SA's (NASDAQ: ABVX) stock is trading higher on Wednesday. The stock reacted to market rumours that U.S. pharma giant Eli Lilly and Co (NYSE:LLY) could make an offer.
French biotech Abivax's shares climb on Eli Lilly bid rumors
French biotech company Abivax's shares jumped by 20% on Wednesday on market rumours that U.S. pharma giant Eli Lilly might be interested in bidding for the business.